Holen Sie sich die Stockscreener-App
26.91
2.00%
-0.595
Schlusskurs vom Vortag:
$27.51
Offen:
$27.41
24-Stunden-Volumen:
360.04K
Relative Volume:
0.25
Marktkapitalisierung:
$4.55B
Einnahmen:
$890.53M
Nettoeinkommen (Verlust:
$30.57M
KGV:
149.53
EPS:
0.18
Netto-Cashflow:
$80.53M
1W Leistung:
+3.73%
1M Leistung:
-3.13%
6M Leistung:
+15.86%
1J Leistung:
+41.30%
1-Tages-Spanne:
$26.80
$27.81
1-Wochen-Bereich:
$25.25
$27.81
52-Wochen-Spanne:
$13.40
$28.35
Acadia Pharmaceuticals Inc Stock (ACAD) Company Profile
Firmenname
Acadia Pharmaceuticals Inc
Sektor
Branche
Telefon
858-558-2871
Adresse
12830 EL CAMINO REAL, SAN DIEGO
Vergleichen Sie ACAD mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ACAD
Acadia Pharmaceuticals Inc
|
26.92 | 4.65B | 890.53M | 30.57M | 80.53M | 0.18 |
|
VRTX
Vertex Pharmaceuticals Inc
|
463.95 | 118.58B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
749.78 | 79.40B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
811.57 | 51.18B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
360.78 | 48.88B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
339.19 | 37.49B | 4.98B | 69.59M | 525.67M | 0.5197 |
Acadia Pharmaceuticals Inc Stock (ACAD) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-21 | Eingeleitet | Citigroup | Buy |
| 2025-05-21 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2025-02-11 | Eingeleitet | Deutsche Bank | Hold |
| 2025-01-03 | Herabstufung | Guggenheim | Buy → Neutral |
| 2024-10-10 | Fortgesetzt | Raymond James | Mkt Perform |
| 2024-08-07 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2024-06-27 | Eingeleitet | BMO Capital Markets | Outperform |
| 2024-03-12 | Herabstufung | Mizuho | Buy → Neutral |
| 2024-03-12 | Bestätigt | Needham | Buy |
| 2024-01-30 | Eingeleitet | Robert W. Baird | Outperform |
| 2024-01-24 | Hochstufung | Needham | Hold → Buy |
| 2023-12-19 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2023-12-14 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2023-12-13 | Eingeleitet | Citigroup | Buy |
| 2023-12-12 | Eingeleitet | Deutsche Bank | Buy |
| 2023-11-06 | Hochstufung | Mizuho | Neutral → Buy |
| 2023-10-17 | Eingeleitet | UBS | Buy |
| 2023-10-10 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2023-01-03 | Hochstufung | Guggenheim | Neutral → Buy |
| 2022-11-04 | Herabstufung | Goldman | Neutral → Sell |
| 2022-11-01 | Eingeleitet | Loop Capital | Hold |
| 2022-08-08 | Herabstufung | Citigroup | Buy → Neutral |
| 2022-08-05 | Herabstufung | Citigroup | Buy → Neutral |
| 2022-06-21 | Herabstufung | Jefferies | Buy → Underperform |
| 2022-06-16 | Hochstufung | Jefferies | Hold → Buy |
| 2022-03-16 | Hochstufung | Canaccord Genuity | Hold → Buy |
| 2022-02-09 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2022-01-05 | Hochstufung | Citigroup | Neutral → Buy |
| 2021-12-21 | Herabstufung | Guggenheim | Buy → Neutral |
| 2021-11-01 | Hochstufung | Guggenheim | Neutral → Buy |
| 2021-10-14 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-09-23 | Fortgesetzt | Needham | Hold |
| 2021-06-10 | Eingeleitet | Berenberg | Hold |
| 2021-04-07 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2021-04-06 | Herabstufung | Canaccord Genuity | Buy → Hold |
| 2021-04-06 | Herabstufung | Goldman | Buy → Neutral |
| 2021-04-06 | Herabstufung | Jefferies | Buy → Hold |
| 2021-04-06 | Herabstufung | Mizuho | Buy → Neutral |
| 2021-04-05 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2021-03-10 | Herabstufung | BofA Securities | Buy → Neutral |
| 2021-03-09 | Herabstufung | Citigroup | Buy → Neutral |
| 2021-03-09 | Herabstufung | Guggenheim | Buy → Neutral |
| 2021-03-09 | Bestätigt | H.C. Wainwright | Buy |
| 2021-03-09 | Herabstufung | Raymond James | Strong Buy → Outperform |
| 2021-03-09 | Herabstufung | Stifel | Buy → Hold |
| 2020-12-16 | Eingeleitet | Mizuho | Buy |
| 2020-11-16 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2020-08-25 | Eingeleitet | Raymond James | Outperform |
| 2020-08-20 | Eingeleitet | Morgan Stanley | Overweight |
| 2020-07-07 | Hochstufung | Stifel | Hold → Buy |
| 2020-04-16 | Eingeleitet | Jefferies | Buy |
| 2020-03-31 | Hochstufung | Goldman | Neutral → Buy |
| 2020-03-06 | Eingeleitet | Citigroup | Buy |
| 2019-12-16 | Eingeleitet | Guggenheim | Buy |
| 2019-10-24 | Eingeleitet | Oppenheimer | Perform |
| 2019-10-01 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2019-09-13 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2019-09-10 | Hochstufung | Canaccord Genuity | Hold → Buy |
| 2019-07-23 | Bestätigt | Needham | Buy |
| 2018-12-10 | Eingeleitet | Canaccord Genuity | Hold |
| 2018-09-21 | Hochstufung | Piper Jaffray | Neutral → Overweight |
| 2018-08-09 | Bestätigt | Stifel | Hold |
| 2018-08-07 | Eingeleitet | Stifel | Hold |
| 2018-08-06 | Herabstufung | Piper Jaffray | Overweight → Neutral |
| 2017-10-06 | Fortgesetzt | Goldman | Neutral |
Alle ansehen
Acadia Pharmaceuticals Inc Aktie (ACAD) Neueste Nachrichten
Analysts Offer Insights on Healthcare Companies: Boston Scientific (BSX) and ACADIA Pharmaceuticals (ACAD) - The Globe and Mail
Gains Recap: What is the target price for ACADIA Pharmaceuticals Inc stockQuarterly Profit Report & Free Community Consensus Stock Picks - baoquankhu1.vn
Discipline and Rules-Based Execution in ACAD Response - Stock Traders Daily
Campbell & CO Investment Adviser LLC Takes $838,000 Position in ACADIA Pharmaceuticals Inc. $ACAD - MarketBeat
Axecap Investments LLC Purchases New Position in ACADIA Pharmaceuticals Inc. $ACAD - MarketBeat
Assessing Acadia Pharmaceuticals (ACAD) Valuation After New Long Term Sales And Pipeline Targets - Sahm
Investing in ACADIA Pharmaceuticals (NASDAQ:ACAD) a Year Ago Would Have Delivered You a 51% Gain - 富途资讯
ACADIA PHARMACEUTICALS INC (NASDAQ:ACAD) Shows Strong Growth Momentum and Technical Setup - Chartmill
Is It Time To Reconsider ACADIA Pharmaceuticals (ACAD) After Recent Share Price Weakness - Sahm
A Look At ACADIA Pharmaceuticals (ACAD) Valuation After Recent Share Price Swings - Yahoo Finance
Is It Time To Reassess ACADIA Pharmaceuticals (ACAD) After Its Recent Share Price Surge - Yahoo Finance
JPM26 Day 2: Companies Lay Out Near-Term Revenue, Longer-Term Business Goals - BioSpace
Acadia projects $1.7 billion in 2028 sales for NUPLAZID and DAYBUE - Investing.com Nigeria
Neuren Pharmaceuticals flags DAYBUE global sales potential of US$700m by 2028 - Proactive financial news
Acadia Pharmaceuticals (ACAD) Projects Over $1B in 2025 Sales - GuruFocus
ACADIA Pharmaceuticals Clarifies Form 8-K Disclosure Treatment - TipRanks
Acadia Pharma anticipates 2025 net sales to exceed $1 billion - StreetInsider
ACADIA Pharmaceuticals Targets $1.7B Sales by 2028, Maps Key Remlifansirin Readouts at JPM Conf - MarketBeat
Acadia CEO Bands With Peers To Lobby Against MFN Drug Pricing for Small Biotech - BioSpace
ACADIA projects $1.7 billion in 2028 sales, launches new DAYBUE formulation - StreetInsider
Acadia Pharmaceuticals Provides Business And Pipeline Updates At 44Th Annual J.P. Morgan Healthcare Conference - TradingView — Track All Markets
Acadia Pharmaceuticals Provides Business and Pipeline Updates at 44th Annual J.P. Morgan Healthcare Conference - Yahoo Finance
Lobbying Update: $30,000 of ACADIA PHARMACEUTICALS lobbying was just disclosed - Quiver Quantitative
Published on: 2026-01-13 01:54:16 - Улправда
Acadia Pharmaceuticals Focuses on Next-Gen Neuroscience - marketscreener.com
Watch Acadia Pharmaceuticals Focuses on Next-Gen Neuroscience - Bloomberg
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Wall Street Zen Upgrades ACADIA Pharmaceuticals (NASDAQ:ACAD) to "Buy" - MarketBeat
Behavioral Patterns of ACAD and Institutional Flows - Stock Traders Daily
ACAD Q3 Earnings Beat, Nuplazid & Daybue Drive Y/Y Revenue Growth - MSN
Can ACADIA Pharmaceuticals Inc. stock attract ESG capital inflows2025 Analyst Calls & Growth Focused Stock Pick Reports - ulpravda.ru
How ACADIA Pharmaceuticals Inc. stock compares to industry benchmarks2025 Market Outlook & AI Driven Stock Reports - Улправда
Acadia drops development of carbetocin in PWS - The Pharma Letter
Pullback Watch: Will ACADIA Pharmaceuticals Inc. stock outperform international peersJuly 2025 Review & Fast Gain Stock Trading Tips - ulpravda.ru
Will ACADIA Pharmaceuticals Inc. stock beat EPS estimatesProduct Launch & Risk Adjusted Swing Trade Ideas - ulpravda.ru
Will ACADIA Pharmaceuticals Inc. stock see PE expansionTrade Performance Summary & Reliable Price Breakout Signals - Улправда
Is ACADIA Pharmaceuticals Inc. stock a defensive play in 2025Forecast Cut & Free Reliable Trade Execution Plans - Улправда
Stock Market Recap: Will ACADIA Pharmaceuticals Inc. stock outperform international peersJuly 2025 Drop Watch & AI Powered Buy and Sell Recommendations - ulpravda.ru
Assessing ACADIA Pharmaceuticals (ACAD) Valuation After Recent Share Price Momentum - Sahm
ACADIA Pharmaceuticals (ACAD) Sees Target Price Raised by Citigr - GuruFocus
UBS Raises Price Target to $40 for ACADIA Pharmaceuticals (ACAD) - GuruFocus
ACADIA Pharmaceuticals Inc. $ACAD Shares Purchased by Allspring Global Investments Holdings LLC - MarketBeat
ACADIA Pharmaceuticals (NASDAQ:ACAD) Cut to "Hold" at Wall Street Zen - MarketBeat
What drives ACADIA Pharmaceuticals Inc stock priceMean Reversion Trades & Outstanding Wealth Building - earlytimes.in
ACADIA Pharmaceuticals Earnings Notes - Trefis
Insider Sell: Is ACADIA Pharmaceuticals Inc stock in correction or buying zoneIndex Update & Risk Controlled Swing Alerts - moha.gov.vn
(ACAD) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
Deutsche Bank Upgrades ACADIA Pharmaceuticals (ACAD) - MSN
Performance Recap: Can ACADIA Pharmaceuticals Inc stock hit analyst price targetsWeekly Earnings Recap & Verified Swing Trading Watchlists - moha.gov.vn
Rice Hall James & Associates LLC Sells 54,869 Shares of ACADIA Pharmaceuticals Inc. $ACAD - MarketBeat
ACADIA Pharmaceuticals Inc. $ACAD Holdings Decreased by Assenagon Asset Management S.A. - MarketBeat
Finanzdaten der Acadia Pharmaceuticals Inc-Aktie (ACAD)
Umsatz
Nettogewinn
Free Cashflow
ENV
4.38%
1.95%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):